



Potential of KLS-13019 to Serve as Non-Addicting and Non-Opioid Option for Neuropathic and Chronic Pain Relief

Dean Petkanas

Kannalife, Inc., USA

According to the White House drug policy office, drug-related fatalities increased by [11.4%](#) year-over-year in the first four months of 2020. As opioid overdose deaths skyrocket across the U.S. during the COVID-19 pandemic, emphasis needs to be placed on proactively creating non-opioid solutions for pain relief. [Kannalife, Inc.](#), a biopharmaceutical and medchem company specializing in the research and development of potent novel monotherapeutics, has been working on a non-opioid solution for pain through its laboratory-created cannabidiol (CBD)-like molecule KLS-13019. In research funded by a [grant](#) from the National Institutes of Health's National Institute on Drug Abuse.



Dean Petkanas, Chairman and CEO of Kannalife, Inc., is a biotech industry professional with 20+ years of experience. He co-founded Kannalife in 2010 & co-invented 7 patents of novel cannabidiol-like non-opioid monotherapeutics focused on treating pain, neurodegeneration and oxidative stress-related diseases

Cannabinoids as Antioxidants and Neuroprotectants
Functionalized 1,3 Benzene-diols and their Method of Use for the Treatment of Hepatic Encephalopathy.
Method for Treating Hepatic Encephalopathy or a Disease Associated with Free Radical Mediate Stress and Oxidative Stress with Novel Functionalized 1,3 Benzene-diols.

7. [4th international conference on cannabis and medicinal Research, September 21-22,2020, Sydney, Australia](#)

8. [Dean Petkanas, Potential of KLS-13019 to Serve as Non-Addicting and Non-Opioid Option for Neuropathic and Chronic Pain Relief, cannabis marijuana 2020, September 21-22,2020, Sydney, Australia](#)